

JÃ³zsef TÃ¡-mÃ¡r

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2004108/publications.pdf>

Version: 2024-02-01

135
papers

6,075
citations

53751

45
h-index

88593

70
g-index

154
all docs

154
docs citations

154
times ranked

8399
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of a Tumor Cell Associated Type I IFN Resistance Gene Expression Signature of Human Melanoma, the Components of Which Have a Predictive Potential for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2704.	1.8	3
2	Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5384.	1.8	28
3	The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation. <i>Translational Lung Cancer Research</i> , 2021, 10, 675-684.	1.3	3
4	EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study. <i>Translational Lung Cancer Research</i> , 2021, 10, 662-674.	1.3	17
5	Hypoxia Signaling in Cancer: From Basics to Clinical Practice. <i>Pathology and Oncology Research</i> , 2021, 27, 1609802.	0.9	46
6	A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures. <i>Npj Precision Oncology</i> , 2021, 5, 55.	2.3	16
7	The human melanoma proteome atlas – Defining the molecular pathology. <i>Clinical and Translational Medicine</i> , 2021, 11, e473.	1.7	14
8	The Human Melanoma Proteome Atlas – Complementing the melanoma transcriptome. <i>Clinical and Translational Medicine</i> , 2021, 11, e451.	1.7	20
9	Organ Specific Copy Number Variations in Visceral Metastases of Human Melanoma. <i>Cancers</i> , 2021, 13, 5984.	1.7	7
10	EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy. <i>Pathology and Oncology Research</i> , 2020, 26, 1429-1434.	0.9	7
11	Selective Inhibition of HIF1 α Expression by ZnSO ₄ Has Antitumoral Effects in Human Melanoma. <i>Pathology and Oncology Research</i> , 2020, 26, 673-679.	0.9	4
12	Aquaporin-1 Protein Expression of the Primary Tumor May Predict Cerebral Progression of Cutaneous Melanoma. <i>Pathology and Oncology Research</i> , 2020, 26, 405-410.	0.9	7
13	Immunologic and immunogenomic aspects of tumor progression. <i>Seminars in Cancer Biology</i> , 2020, 60, 249-261.	4.3	35
14	Next Generation Lipophilic Bisphosphonate Shows Antitumor Effect in Colorectal Cancer In Vitro and In Vivo. <i>Pathology and Oncology Research</i> , 2020, 26, 1957-1969.	0.9	10
15	KIT Mutation Incidence and Pattern of Melanoma in Central Europe. <i>Pathology and Oncology Research</i> , 2020, 26, 17-22.	0.9	13
16	Prognostic Impact of the Neutrophil-to-Lymphocyte and Lymphocyte-to-Monocyte Ratio, in Patients with Rectal Cancer: A Retrospective Study of 1052 Patients. <i>Journal of Personalized Medicine</i> , 2020, 10, 173.	1.1	15
17	Molecular epidemiology and diagnostics of KRAS mutations in human cancer. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 1029-1038.	2.7	149
18	Prevalence of APC and PTEN Alterations in Urachal Cancer. <i>Pathology and Oncology Research</i> , 2020, 26, 2773-2781.	0.9	10

#	ARTICLE	IF	CITATIONS
19	Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7649.	1.8	6
20	Guest editorial/preface. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 1017-1017.	2.7	0
21	Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 749-753.	1.4	5
22	EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy. <i>Cancers</i> , 2020, 12, 614.	1.7	6
23	Characterization of cellular and humoral immune responses to alkaline phosphatase from fertile hydatid cysts in the human peripheral blood. <i>Journal of Cellular Physiology</i> , 2019, 234, 2765-2777.	2.0	6
24	Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma. <i>BMC Cancer</i> , 2019, 19, 786.	1.1	12
25	The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4917.	1.8	11
26	KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy. <i>Cancers</i> , 2019, 11, 1514.	1.7	19
27	Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4484.	1.8	18
28	PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis. <i>Clinical Lung Cancer</i> , 2019, 20, 363-369.e2.	1.1	28
29	Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma. <i>Acta OncolÄ³gica</i> , 2019, 58, 1087-1094.	0.8	22
30	Clinical protein science in translational medicine targeting malignant melanoma. <i>Cell Biology and Toxicology</i> , 2019, 35, 293-332.	2.4	33
31	Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1219-1226.	1.2	58
32	<sc>P</sc>athogenic and targetable genetic alterations in 70 urachal adenocarcinomas. <i>International Journal of Cancer</i> , 2018, 143, 1764-1773.	2.3	44
33	Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharyngeal, and Hypopharyngeal Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, e79-e85.	0.6	32
34	NSCLC molecular testing in Central and Eastern European countries. <i>BMC Cancer</i> , 2018, 18, 269.	1.1	28
35	New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study. <i>Lung Cancer</i> , 2018, 126, 139-148.	0.9	25
36	Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model. <i>Melanoma Research</i> , 2018, 28, 536-546.	0.6	20

#	ARTICLE	IF	CITATIONS
37	Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells. <i>BMC Cancer</i> , 2018, 18, 1029.	1.1	34
38	The role of lipid signaling in the progression of malignant melanoma. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 245-255.	2.7	8
39	Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells. <i>BMC Cancer</i> , 2018, 18, 542.	1.1	16
40	Alteration of mutant allele frequency in visceral metastases of melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21528-e21528.	0.8	1
41	EGFR protein expression of the metastatic colorectal cancer as a prognostic/predictive factor for anti-EGFR antibody therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15548-e15548.	0.8	1
42	Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. <i>Neuro-Oncology</i> , 2017, 19, 1058-1067.	0.6	38
43	p16INK4 expression is of prognostic and predictive value in oropharyngeal cancers independent of human papillomavirus status: a Hungarian study. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 1959-1965.	0.8	8
44	KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. <i>Scientific Reports</i> , 2017, 7, 39721.	1.6	62
45	<i>RAS</i> mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data. <i>Biomarkers in Medicine</i> , 2017, 11, 751-760.	0.6	33
46	Comparison of immunophenotypes of primary breast carcinomas and multiple corresponding distant metastases: an autopsy study of 25 patients. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 103-113.	1.7	9
47	Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca ²⁺ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK. <i>Frontiers in Oncology</i> , 2017, 7, 95.	1.3	22
48	The phosphomimetic mutation of syndecan-4 binds and inhibits Tiam1 modulating Rac1 activity in PDZ interactionâ€‘dependent manner. <i>PLoS ONE</i> , 2017, 12, e0187094.	1.1	31
49	Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma. <i>Melanoma Research</i> , 2016, 26, 254-260.	0.6	24
50	Significance of Primary Tumor Location and Histology for Brain Metastasis Development and Peritumoral Brain Edema in Lung Cancer. <i>Oncology</i> , 2016, 91, 237-242.	0.9	10
51	Genetic evolution during tumor progression: from basic research to clinical practice. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 3-4.	2.7	0
52	Genetic progression of malignant melanoma. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 93-107.	2.7	60
53	KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. <i>Oncotarget</i> , 2016, 7, 79503-79514.	0.8	11
54	Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurrence and prognostic significance. <i>Oncotarget</i> , 2016, 7, 39293-39301.	0.8	45

#	ARTICLE	IF	CITATIONS
55	Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 738-746.	0.5	70
56	Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells. <i>PLoS ONE</i> , 2015, 10, e0117021.	1.1	19
57	The importance of microenvironment: the role of CCL8 in metastasis formation of melanoma. <i>Oncotarget</i> , 2015, 6, 29111-29128.	0.8	34
58	The clinical relevance of KRAS gene mutation in non-small-cell lung cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 138-144.	1.1	53
59	Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. <i>European Journal of Cancer</i> , 2014, 50, 1819-1828.	1.3	68
60	Molecular testing in lung cancer in the era of precision medicine. <i>Translational Lung Cancer Research</i> , 2014, 3, 291-300.	1.3	38
61	EGFR mutations in lung adenocarcinoma: Epidemiology and clinical relevance of common versus rare mutations.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19067-e19067.	0.8	0
62	Minimal requirements for the molecular testing of lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 301-4.	1.3	14
63	Protein expression differences between lung adenocarcinoma and squamous cell carcinoma with brain metastasis. <i>Anticancer Research</i> , 2014, 34, 5593-7.	0.5	11
64	International biobanking for lung cancer and COPD as the future resource for clinical protein research. <i>EuPA Open Proteomics</i> , 2013, 1, 3-7.	2.5	4
65	Cell migration or cytokinesis and proliferation? â€œ Revisiting the â€œego or growâ€-hypothesis in cancer cells in vitro. <i>Experimental Cell Research</i> , 2013, 319, 3094-3103.	1.2	84
66	Expression of HIF1a and HIF2a in bone metastatic clear cell renal cell cancer and use as prognostic markers.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15523-e15523.	0.8	1
67	Revisiting CB1 Receptor as Drug Target in Human Melanoma. <i>Pathology and Oncology Research</i> , 2012, 18, 857-866.	0.9	21
68	Analysis of colorectal adenocarcinoma tissue by desorption electrospray ionization mass spectrometric imaging. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 403, 2315-2325.	1.9	88
69	RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 1025-1034.	1.1	85
70	A New Mechanism for Pillar Formation during Tumor-Induced Intussusceptive Angiogenesis: Inverse Sprouting. <i>American Journal of Pathology</i> , 2011, 179, 1573-1585.	1.9	59
71	Lack of Angiogenesis in Experimental Brain Metastases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 979-991.	0.9	37
72	Prognostic impact of B-cell density in cutaneous melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1729-1738.	2.0	175

#	ARTICLE	IF	CITATIONS
73	Apelin Expression in Human Non-small Cell Lung Cancer: Role in Angiogenesis and Prognosis. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1120-1129.	0.5	110
74	FOXP3+ Cell Density in Primary Tumor Has No Prognostic Impact in Patients with Cutaneous Malignant Melanoma. <i>Pathology and Oncology Research</i> , 2010, 16, 303-309.	0.9	57
75	Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?. <i>Clinical and Experimental Metastasis</i> , 2010, 27, 371-387.	1.7	69
76	KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence. <i>Current Cancer Drug Targets</i> , 2010, 10, 813-823.	0.8	6
77	Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 108-124.	2.0	58
78	Development of Arterial Blood Supply in Experimental Liver Metastases. <i>American Journal of Pathology</i> , 2009, 175, 835-843.	1.9	39
79	High VEGFR-3â€“positive Circulating Lymphatic/Vascular Endothelial Progenitor Cell Level Is Associated with Poor Prognosis in Human Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 1741-1746.	3.2	45
80	Alternative Vascularization Mechanisms in Cancer. <i>American Journal of Pathology</i> , 2007, 170, 1-15.	1.9	347
81	Functional genomics of calcium channels in human melanoma cells. <i>International Journal of Cancer</i> , 2007, 121, 55-65.	2.3	61
82	Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma. <i>Pathology and Oncology Research</i> , 2007, 13, 21-31.	0.9	30
83	Phenotype of bone metastases of nonsmall cell lung cancer: Epidermal growth factor receptor expression and KRAS mutational status. <i>Pathology and Oncology Research</i> , 2007, 13, 99-104.	0.9	56
84	Density of DC-LAMP+ mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1459-1469.	2.0	236
85	HER-2/neu genotype of breast cancer may change in bone metastasis. <i>Pathology and Oncology Research</i> , 2006, 12, 149-152.	0.9	33
86	Genomics of renal cell cancer â€” Does it provide breakthrough?. <i>Pathology and Oncology Research</i> , 2006, 12, 5-11.	0.9	28
87	Identification and Clinical Significance of Circulating Endothelial Progenitor Cells in Human Nonâ€“Small Cell Lung Cancer. <i>Cancer Research</i> , 2006, 66, 7341-7347.	0.4	168
88	Genomics of lung cancer may change diagnosis, prognosis and therapy. <i>Pathology and Oncology Research</i> , 2005, 11, 5-10.	0.9	18
89	Progression of head and neck squamous cell cancer. <i>Cancer and Metastasis Reviews</i> , 2005, 24, 107-127.	2.7	51
90	Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest. <i>Clinical and Experimental Metastasis</i> , 2005, 22, 69-76.	1.7	33

#	ARTICLE	IF	CITATIONS
91	Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma Modulates Intratumoral CD4/CD8 Ratio and Tumor Microenvironment: A Multicenter Phase II Clinical Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 3421-3432.	0.8	48
92	Recombinant Human Erythropoietin Î± Targets Intratumoral Blood Vessels, Improving Chemotherapy in Human Xenograft Models. <i>Cancer Research</i> , 2005, 65, 7186-7193.	0.4	44
93	Lymphangiogenesis Correlates with Lymph Node Metastasis, Prognosis, and Angiogenic Phenotype in Human Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 7344-7353.	3.2	162
94	Platelet-Mimicry of Cancer Cells: Epiphenomenon with Clinical Significance. <i>Oncology</i> , 2005, 69, 185-201.	0.9	70
95	Associations of ErbB2, Î²1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. <i>Cancer Letters</i> , 2005, 227, 201-212.	3.2	42
96	T-Cell Activation Marker Expression on Tumor-Infiltrating Lymphocytes As Prognostic Factor in Cutaneous Malignant Melanoma. <i>Clinical Cancer Research</i> , 2004, 10, 521-530.	3.2	130
97	In vitro and in vivo antitumor effect of 2-methoxyestradiol on human melanoma. <i>International Journal of Cancer</i> , 2004, 112, 771-776.	2.3	48
98	Molecular identification, localization and function of platelet-type 12-lipoxygenase in human melanoma progression, under experimental and clinical conditions. <i>Melanoma Research</i> , 2004, 14, 245-250.	0.6	25
99	Loss of vascular adhesion protein-1 expression in intratumoral microvessels of human skin melanoma. <i>Melanoma Research</i> , 2004, 14, 135-140.	0.6	24
100	The Effect of Leukocyte Interleukin Injection (Multikine??) Treatment on the Peritumoral and Intratumoral Subpopulation of Mononuclear Cells and on Tumor Epithelia: A Possible New Approach to Augmenting Sensitivity to Radiation Therapy and Chemotherapy in Oral Cancer??? A Multicenter Phase I/II Clinical Trial. <i>Laryngoscope</i> , 2003, 113, 2206-2217.	1.1	18
101	A Novel Concept of Glomeruloid Body Formation in Experimental Cerebral Metastases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 655-661.	0.9	39
102	Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. <i>Seminars in Cancer Biology</i> , 2002, 12, 173-186.	4.3	91
103	Role of elastin-“matrix interactions in tumor progression. <i>Seminars in Cancer Biology</i> , 2002, 12, 209-217.	4.3	61
104	Role for Î²3 integrins in human melanoma growth and survival. <i>International Journal of Cancer</i> , 2002, 101, 156-167.	2.3	51
105	Molecular pathology of tumor metastasis. <i>Pathology and Oncology Research</i> , 2002, 8, 204-219.	0.9	29
106	Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. <i>Journal of Pathology</i> , 2002, 197, 355-362.	2.1	109
107	Multiple roles for platelet GPIIb/IIIa and Î±vÎ²3 integrins in tumor growth, angiogenesis, and metastasis. <i>Cancer Research</i> , 2002, 62, 2824-33.	0.4	164
108	Ectopic Î±IIbÎ²3 Integrin Signaling Involves 12-Lipoxygenase and PKC-mediated Serine Phosphorylation Events in Melanoma Cells. <i>Thrombosis and Haemostasis</i> , 2001, 85, 1037-1042.	1.8	29

#	ARTICLE	IF	CITATIONS
109	Angiogenesis-dependent diseases and angiogenesis therapy. Pathology and Oncology Research, 2001, 7, 85-94.	0.9	74
110	Constitutive intracellular expression and activation-induced cell surface up-regulation of CD44v3 in human T lymphocytes. European Journal of Immunology, 2001, 31, 600-608.	1.6	20
111	Expression of CD44v3 splice variant is associated with the visceral metastatic phenotype of human melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 439, 628-635.	1.4	27
112	Expression, subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. International Journal of Cancer, 2000, 87, 37-43.	2.3	68
113	Histidine Decarboxylase Expression in Human Melanoma. Journal of Investigative Dermatology, 2000, 115, 345-352.	0.3	61
114	Caveolin isoforms in resident and elicited rat peritoneal macrophages. European Journal of Cell Biology, 2000, 79, 343-349.	1.6	26
115	Organ-specificity of the extravasation process: an ultrastructural study. Clinical and Experimental Metastasis, 2000, 18, 481-492.	1.7	53
116	Tumor sinuses - vascular channels. Pathology and Oncology Research, 2000, 6, 83-86.	0.9	26
117	Autocrine motility factor (neuroleukin, phosphohexose isomerase) induces cell movement through 12-lipoxygenase-dependent tyrosine phosphorylation and serine dephosphorylation events. Clinical and Experimental Metastasis, 1999, 17, 809-816.	1.7	12
118	Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. Molecular and Cellular Biochemistry, 1998, 183, 11-23.	1.4	53
119	Role of $\alpha 5 \beta 3$ integrin in prostate cancer metastasis. , 1998, 35, 185-192.		47
120	Expression of invasion markers CD44v6/v3, NM23 and MMP2 in laryngeal and hypopharyngeal carcinoma. Pathology and Oncology Research, 1998, 4, 14-21.	0.9	24
121	BMD188, A novel hydroxamic acid compound, demonstrates potent anti-prostate cancer effects in vitro and in vivo by inducing apoptosis: requirements for mitochondria, reactive oxygen species, and proteases. Pathology and Oncology Research, 1998, 4, 179-190.	0.9	20
122	Expression and function of the high affinity $\alpha 5 \beta 3$ integrin in murine melanoma cells. Clinical and Experimental Metastasis, 1997, 16, 437-445.	1.7	14
123	Ectopic expression of platelet integrin $\alpha 5 \beta 3$ in tumor cells from various species and histological origin. , 1997, 72, 642-648.		58
124	Modulation of heparan-sulphate/chondroitin-sulphate ratio by glycosaminoglycan biosynthesis inhibitors affects liver metastatic potential of tumor cells. International Journal of Cancer, 1995, 62, 755-761.	2.3	21
125	12-Lipoxygenases and 12(S)-HETE: role in cancer metastasis. Cancer and Metastasis Reviews, 1994, 13, 365-396.	2.7	198
126	A Lipoxygenase Metabolite, 12-(S)-HETE, Stimulates Protein Kinase C-Mediated Release of Cathepsin B from Malignant Cells. Experimental Cell Research, 1994, 214, 120-130.	1.2	105

#	ARTICLE	IF	CITATIONS
127	Regulation of melanoma-cell motility by the lipoxygenase metabolite 12-(S)-hete. International Journal of Cancer, 1993, 55, 1003-1010.	2.3	71
128	Effect of lentinan on macrophage cytotoxicity against metastatic tumor cells. Cancer Immunology, Immunotherapy, 1993, 36, 123-126.	2.0	60
129	The Lipoxygenase Metabolite, 12(S)-HETE, Induces a Protein Kinase C-Dependent Cytoskeletal Rearrangement and Retraction of Microvascular Endothelial Cells. Experimental Cell Research, 1993, 207, 361-375.	1.2	52
130	Î±IIbÎ²3 Integrin expression and function in subpopulations of murine tumors. Experimental Cell Research, 1992, 201, 23-32.	1.2	46
131	Is there a role for the tumor cell integrin Î±IIbÎ²3 and cytoskeleton in tumor cell-platelet interaction?. Clinical and Experimental Metastasis, 1992, 10, 125-137.	1.7	32
132	Protein-kinase-C inhibitor calphostin C reduces B16 amelanotic melanoma cell adhesion to endothelium and lung colonization. International Journal of Cancer, 1992, 52, 147-152.	2.3	45
133	The lipoxygenase metabolite 12(S)-hete promotes Î±IIbÎ²3 integrin-mediated tumor-cell spreading on fibronectin. International Journal of Cancer, 1992, 52, 594-603.	2.3	63
134	The lipoxygenase metabolite 12(S)-hete induces a cytoskeleton-dependent increase in surface expression of integrin Î±IIbÎ²3 on melanoma cells. International Journal of Cancer, 1991, 49, 774-786.	2.3	91
135	Opposite prognostic roles of HIF1Î± and HIF2Î± expressions in bone metastatic clear cell renal cell cancer. Oncotarget, 0, 7, 42086-42098.	0.8	19